Spyro Mousses

Summary

Affiliation: Translational Genomics Research Institute
Country: USA

Publications

  1. pmc The BioIntelligence Framework: a new computational platform for biomedical knowledge computing
    Toni Farley
    The Translational Genomics Research Institute TGen, Center for BioIntelligence, Phoenix, AZ 85004, USA
    J Am Med Inform Assoc 20:128-33. 2013
  2. pmc Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer
    David O Azorsa
    Pharmaceutical Genomics Division, The Translational Genomics Research Institute, Scottsdale, Arizona 85259, USA
    J Transl Med 7:43. 2009
  3. pmc Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication
    Maija Wolf
    Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland
    BMC Cancer 10:181. 2010
  4. pmc RNAi microarray analysis in cultured mammalian cells
    Spyro Mousses
    Cancer Drug Development Laboratory, Translational Genomics Research Institute TGen, Gaithersburg, Maryland 20878, USA
    Genome Res 13:2341-7. 2003
  5. ncbi request reprint Harnessing the power of RNA interference to advance anticancer drug development
    Spyro Mousses
    Cancer Drug Development Laboratory, Translational Genomics Research Institute, Gaithersburg, Maryland 20878, USA
    Mol Cancer Ther 2:217-8. 2003
  6. pmc High-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells
    Meredith C Henderson
    Clinical Translational Research Division, Translational Genomics Research Institute, Scottsdale, AZ 85259, USA
    Mol Cancer Res 9:724-32. 2011
  7. pmc RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma
    Shilpi Arora
    Pharmaceutical Genomic Division, Translational Genomics Research Institute, Scottsdale, AZ 85259, USA
    Mol Cancer 9:218. 2010
  8. doi request reprint RNAi-based functional pharmacogenomics
    Sukru Tuzmen
    Pharmaceutical Genomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA
    Methods Mol Biol 700:271-90. 2011
  9. ncbi request reprint Integration of genomic technologies for accelerated cancer drug development
    Mark Basik
    Translational Genomics Research Institute, Gaithersburg, MD, USA
    Biotechniques 35:580-2, 584, 586 passim. 2003
  10. doi request reprint High-throughput siRNA screening as a method of perturbation of biological systems and identification of targeted pathways coupled with compound screening
    Jeff Kiefer
    Pharmaceutical Genomics Division, Translational Genomics Research Institute TGen, Phoenix, AZ, USA
    Methods Mol Biol 563:275-87. 2009

Collaborators

Detail Information

Publications32

  1. pmc The BioIntelligence Framework: a new computational platform for biomedical knowledge computing
    Toni Farley
    The Translational Genomics Research Institute TGen, Center for BioIntelligence, Phoenix, AZ 85004, USA
    J Am Med Inform Assoc 20:128-33. 2013
    ....
  2. pmc Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer
    David O Azorsa
    Pharmaceutical Genomics Division, The Translational Genomics Research Institute, Scottsdale, Arizona 85259, USA
    J Transl Med 7:43. 2009
    ..Combinations of gemcitabine with other chemotherapeutic drugs or biological agents have resulted in limited improvement...
  3. pmc Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication
    Maija Wolf
    Institute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland
    BMC Cancer 10:181. 2010
    ..Here, we present a framework, which integrates DNA, RNA and tissue data to identify and prioritize genetic events that represent clinically relevant new therapeutic targets and prognostic biomarkers for neuroblastoma...
  4. pmc RNAi microarray analysis in cultured mammalian cells
    Spyro Mousses
    Cancer Drug Development Laboratory, Translational Genomics Research Institute TGen, Gaithersburg, Maryland 20878, USA
    Genome Res 13:2341-7. 2003
    ..In summary, this RNAi microarray platform, together with ongoing efforts to develop large-scale human siRNA libraries, should facilitate genomic-scale cell-based analyses of gene function...
  5. ncbi request reprint Harnessing the power of RNA interference to advance anticancer drug development
    Spyro Mousses
    Cancer Drug Development Laboratory, Translational Genomics Research Institute, Gaithersburg, Maryland 20878, USA
    Mol Cancer Ther 2:217-8. 2003
  6. pmc High-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells
    Meredith C Henderson
    Clinical Translational Research Division, Translational Genomics Research Institute, Scottsdale, AZ 85259, USA
    Mol Cancer Res 9:724-32. 2011
    ..The application of functional genomics by using HT-RNAi screens has allowed us to identify TNK1 as a growth-associated kinase in pancreatic cancer cells...
  7. pmc RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma
    Shilpi Arora
    Pharmaceutical Genomic Division, Translational Genomics Research Institute, Scottsdale, AZ 85259, USA
    Mol Cancer 9:218. 2010
    ..As part of novel target discovery in Ewing's sarcoma, we applied RNAi mediated phenotypic profiling to identify kinase targets involved in growth and survival of Ewing's sarcoma cells...
  8. doi request reprint RNAi-based functional pharmacogenomics
    Sukru Tuzmen
    Pharmaceutical Genomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA
    Methods Mol Biol 700:271-90. 2011
    ..In this chapter, we focus on the application of RNAi, with particular focus on HT siRNA phenotype profiling, to support cellular pharmacogenomics...
  9. ncbi request reprint Integration of genomic technologies for accelerated cancer drug development
    Mark Basik
    Translational Genomics Research Institute, Gaithersburg, MD, USA
    Biotechniques 35:580-2, 584, 586 passim. 2003
    ..This review examines the use of new and emerging DNA, tissue, and live-cell transfection microarray technologies that can be used to discover, validate, and translate information resulting from the completion of the Human Genome Project...
  10. doi request reprint High-throughput siRNA screening as a method of perturbation of biological systems and identification of targeted pathways coupled with compound screening
    Jeff Kiefer
    Pharmaceutical Genomics Division, Translational Genomics Research Institute TGen, Phoenix, AZ, USA
    Methods Mol Biol 563:275-87. 2009
    ..Most importantly, pathway tools allow the interrogation of HT-RNAi data to identify and prioritize pathway-based biological information as a result of specific loss of gene function...
  11. pmc High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation
    David O Azorsa
    Pharmaceutical Genomics Division, Translational Genomics Research Institute, Scottsdale, Arizona 85251, USA
    BMC Genomics 11:25. 2010
    ..Identifying the kinases involved in the pathologic phosphorylation of tau may provide targets at which to aim new AD-modifying treatments...
  12. pmc Advancing a clinically relevant perspective of the clonal nature of cancer
    Christian Ruiz
    Clinical Translational Research Division, Translational Genomics Research Institute, Scottsdale, AZ 85259, USA
    Proc Natl Acad Sci U S A 108:12054-9. 2011
    ..We propose that our high-definition analyses of the genomes of distinct clonal populations of cancer cells in patients in vivo can help guide diagnoses and tailor approaches to personalized treatment...
  13. ncbi request reprint Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer
    Pia Huusko
    Translational Genomics Research Institute, Cancer Drug Development Laboratory, 20 Firstfield Road, Suite 110, Gaithersburg, Maryland 20878, USA
    Nat Genet 36:979-83. 2004
    ....
  14. ncbi request reprint Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents
    Hong Wang
    The Translational Genomics Research Institute, Translational Drug Development Division, Phoenix, AZ 85004, USA
    Semin Oncol 33:513-20. 2006
    ..In this review, we discuss the feasibility of targeting loss-of-function mutations in tumor-suppressor genes for the identification of cancer-specific therapeutic agents...
  15. ncbi request reprint Genome scale cytometry: High content analysis for high throughput RNAi phenotype profiling
    David M Evans
    Cancer Drug Development Laboratory, Translational Genomics Research Institute, 20, Firstfield Rd, Gaithersburg, MD 20878, USA Electronic
    Drug Discov Today Technol 2:141-7. 2005
    ..This review examines the current status of research in combining these tools.: ..
  16. ncbi request reprint Pancreatic cancer--could it be that simple? A different context of vulnerability
    Daniel D Von Hoff
    Translational Genomics Research Institute, Phoenix, AZ 85004, USA
    Cancer Cell 16:7-8. 2009
    ..Could this finding provide us with a new method to attack pancreatic cancer?..
  17. ncbi request reprint A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
    John D Carpten
    Division of Integrated Cancer Genomics, Translational Genomics Research Institute, 445 N Fifth Street, Phoenix, Arizona 85004, USA
    Nature 448:439-44. 2007
    ..Furthermore, the E17K substitution decreases the sensitivity to an allosteric kinase inhibitor, so this mutation may have important clinical utility for AKT drug development...
  18. ncbi request reprint NMD microarray analysis for rapid genome-wide screen of mutated genes in cancer
    Maija Wolf
    Medical Biotechnology, VTT Technical Research Centre of Finland and University of Turku, FIN 20520 Turku, Finland
    Cell Oncol 27:169-73. 2005
    ....
  19. pmc High-resolution analysis of gene copy number alterations in human prostate cancer using CGH on cDNA microarrays: impact of copy number on gene expression
    Maija Wolf
    Medical Biotechnology, VTT Technical Research Centre of Finland and University of Turku, Turku FIN 20520, Finland
    Neoplasia 6:240-7. 2004
    ....
  20. ncbi request reprint Validation of short interfering RNA knockdowns by quantitative real-time PCR
    Sukru Tuzmen
    Pharmaceutical Genomics Division, Translational Genomics Institute, Scottsdale, AZ, USA
    Methods Mol Biol 353:177-203. 2007
    ....
  21. ncbi request reprint Impact of DNA amplification on gene expression patterns in breast cancer
    Elizabeth Hyman
    Howard Hughes Medical Institute NIH Research Scholar, Bethesda, Maryland 20892, USA
    Cancer Res 62:6240-5. 2002
    ..These genes may provide insights to the clonal evolution and progression of breast cancer and highlight promising therapeutic targets...
  22. doi request reprint Functional evidence implicating S100P in prostate cancer progression
    Gargi D Basu
    Pharmaceutical Genomics Division, The Translational Genomics Research Institute, Scottsdale, AZ 85259, USA
    Int J Cancer 123:330-9. 2008
    ..Hence, S100P could be considered a potential drug target or a chemosensitization target, and could also serve as a biomarker for aggressive, hormone-refractory and metastatic prostate cancer...
  23. ncbi request reprint New insights into testicular germ cell tumorigenesis from gene expression profiling
    Rolf I Skotheim
    Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, N 0310 Oslo, Norway
    Cancer Res 62:2359-64. 2002
    ....
  24. doi request reprint Discovery of genetic profiles impacting response to chemotherapy: application to gemcitabine
    Hamdi Jarjanazi
    Fred A Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Toronto, Ontario, Canada
    Hum Mutat 29:461-7. 2008
    ..The results obtained using this novel methodology can be used to better design the clinical trials for effective study of the chemotherapeutic agents and thus provide a basis for individualized chemotherapy...
  25. ncbi request reprint Intersex-like (IXL) is a cell survival regulator in pancreatic cancer with 19q13 amplification
    Riina Kuuselo
    Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland
    Cancer Res 67:1943-9. 2007
    ..These findings implicate IXL as a novel amplification target gene in pancreatic cancer and suggest that IXL is required for cancer cell survival in 19q13-amplified tumors...
  26. ncbi request reprint Identification of molecular markers for endometriosis in blood lymphocytes by using deoxyribonucleic acid microarrays
    Idhaliz Flores
    Department of Microbiology, Ponce School of Medicine, Ponce, Puerto Rico
    Fertil Steril 85:1676-83. 2006
    ..To identify molecular biomarkers for endometriosis in peripheral blood lymphocytes by using DNA microarrays...
  27. ncbi request reprint EphB2 expression across 138 human tumor types in a tissue microarray: high levels of expression in gastrointestinal cancers
    Alessandro Lugli
    Institute of Pathology, University Hospital and Institute of Clinical Pathology, Basel, Switzerland
    Clin Cancer Res 11:6450-8. 2005
    ..To comprehensively evaluate ephrin receptor B2 (EphB2) expression in normal and neoplastic tissues. EphB2 is a tyrosine kinase recently implicated in the deregulation of cell-to-cell communication in many tumors...
  28. ncbi request reprint Short interfering RNA (siRNA)-mediated RNA interference (RNAi) in human cells
    Natasha J Caplen
    Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Ann N Y Acad Sci 1002:56-62. 2003
    ....
  29. ncbi request reprint Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome
    Rolf I Skotheim
    Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital and University of Oslo, Norway
    J Clin Oncol 21:4586-91. 2003
    ..To identify target genes of clinical significance for patients with malignant peripheral-nerve sheath tumor (MPNST), an aggressive cancer for which no consensus therapy exists...
  30. ncbi request reprint Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells
    Iris E Eder
    Department of Urology, University of Innsbruck, Innsbruck, Austria
    Mol Carcinog 37:181-91. 2003
    ..Further investigations are warranted to clarify their role in the AR signaling pathway and their susceptibility as a target for the treatment of prostate cancer...
  31. ncbi request reprint Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays
    Spyro Mousses
    Cancer Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 62:1256-60. 2002
    ..001). These results illustrate a strategy for rapid clinical validation at the mRNA and protein level of gene targets found to be differentially expressed in cDNA microarray experiments of model systems of cancer...
  32. ncbi request reprint Clinical and functional target validation using tissue and cell microarrays
    Spyro Mousses
    Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892 8000, USA
    Curr Opin Chem Biol 6:97-101. 2002
    ..New high-throughput techniques, such as tissue and cell microarrays, will facilitate clinical and functional analysis of molecular targets...